Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
15.64
+0.56 (3.71%)
Jul 10, 2025, 4:00 PM - Market closed

Maze Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022
Period Ending
Jul '25 Dec '24 Dec '23 Dec '22
685---
Enterprise Value
416---
Debt / Equity Ratio
0.090.144.940.32
Debt / EBITDA Ratio
0.440.40--
Debt / FCF Ratio
0.380.36--
Asset Turnover
-1.07--
Quick Ratio
15.819.521.794.81
Current Ratio
16.109.762.095.11
Return on Equity (ROE)
34.38%50.48%-180.12%-
Return on Assets (ROA)
-23.07%-55.63%-
Return on Capital (ROIC)
16.62%25.42%-63.77%-
Return on Capital Employed (ROCE)
16.00%26.20%--
Buyback Yield / Dilution
-303.36%-19.33%-13.82%-
Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q